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DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING
June 17-18, 2020

Executive Summary
NM Highlights: NM case count. UNM housing plan for fall 2020. Navajo Nation health and social inequities.
US Highlights: Banning airline passengers.
Economics, Workforce, Supply Chain, PPE: COVID-19 Exit Strategy. Effect of extended use respirators and PPE.
Epidemiology Highlights: Model predicts effects of strategies on US epidemic. Index for assessing risk of
contagion.
Practice Guidelines: Institutional antithrombotic protocols in US and France are reviewed. Shortcomings of
restricted hospital visitation are discussed.
Testing: Current testing strategies and assays. Reducing transmission in incarcerated populations.
Drugs, Vaccines, Therapies, Clinical Trials: More detail on dexamethasone trial. Methylprednisolone
improved outcomes. Outcomes on ACEI/ARB. 34 new trials.
Other Science: Nearly 20% of world’s population is at risk for severe disease. High-flow nasal cannula for acute
respiratory failure. Genome-wide association study of patients with severe disease. Frail geriatric COVID-19
patients have a higher risk of delirium. Asymptomatic infection is associated with a longer virus shedding and a
weaker immune response.
All of our past briefings are maintained in a UNM library repository here.
Our continuously curated practice guidelines in the context of COVID-19 can be found here.
Our continuously curated therapeutic evidence is maintained here.
You may submit content for future briefings here.

NM Highlights


NM reports 4 more COVID-19 deaths and 94 additional cases on June 18
As of today (6/18), the total positive cases and total deaths in the state are 10,153 and 456, respectively. The state has
performed 275,897 tests, there are 157 individuals currently hospitalized for COVID-19, and 4,217 COVID-19 cases have
recovered. NMDOH portal featuring epidemiologic breakdown of cases.



UNM plans for on-campus housing for fall 2020
KRQE: UNM announced a plan to bring back on-campus living for students enrolled in Fall 2020 classes, which includes singleoccupancy-only dorm rooms, and having residents agree to social distancing and risk of COVID-19. Priority for living space will
be given to freshmen and those who applied for priority renewal. UNM will still require freshmen to buy meal plans, which
will be distributed as to-go meals and grub hub deliveries if the state ban on buffets and salad bars is still in effect.



A UNM physician treating patients in the hard-hit Navajo nation highlights health and social inequities
U.S.News: The Navajo Nation, home to about 174,000 people as of the last census, has become the epicenter of the novel

coronavirus in the country. As of June 8, the reservation reported 6,110 cases of COVID-19 and 277 deaths – up from 148
cases and five deaths in late March. By mid-May, the Navajo Nation had exceeded New York and New Jersey for the highest
per-capita coronavirus infection rate in the U.S. Experts attribute the startling transmission rates in the Navajo Nation to
health and social inequities, such as a lack of paved roads, inadequate access to running water, high rates of children living in
poverty, underfunded health services.

US Highlights


Major U.S. airlines may ban passengers who refuse to wear masks
Airlines may prevent anyone not wearing a mask from boarding and will provide the coverings to passengers who have none.
Passengers will be informed about the airline's policy on face coverings prior to boarding and onboard. Each airline will
decide the appropriate consequences for passengers failing to comply, which may include being put on the airline’s no-fly
list.

Economics, Workforce, Supply Chain, PPE Highlights


Unlocking towns and cities: COVID-19 exit strategy (Commentary)
Eastern Mediterranean Health Journal (EMHJ): The UK (and WHO) authors discuss the strategies to unlock towns and cities.
While some countries are reporting a decline in new COVID-19 cases, many others are yet to feel the full impact of the virus.
Authors draw the conclusion: Maintaining current aggressive social distancing measures until an effective treatment or
vaccine are available, is not practical. Gradually relaxing restrictions when infection indicators (decreased trans-mission and
spread of the virus) and other conditions are met, could help further easing of measures until the authorities are sure that no
new cases are reported for a reasonable length of time. Governments must ensure that their unlocking plan can be
implemented in practice, clearly communicated and enforced.



Effect of extended use N95 respirators and eye protection on PPE utilization (Letter to Editor)
Antimicrobial Resistance & Infection Control: Prior to 4 February 2020, N95 respirators and eye protection were singlepatient use in Singapore. On 4 February, reusable goggles were issued to each HCW. On 8 February, a directive was issued
recommending extended use of N95respirators and eye protection for repeated encounters with different patients, without
changing between patients unless visibly contaminated or dislodged (Supplementary Appendix Floor Plan). Gowns and gloves
remained as single-patient use. During study period, a daily ward-level stock take calculating the difference in balance PPE
compared to preceding day, accounting for supplies replenished, was defined as utilization rate per day. A daily ward census
was recorded. A total of 77 confirmed and 725 suspect cases were admitted during study period. During the COVID-19
pandemic, the average utilization rate of single-use eye and N95 respirators per 100 patient-days reduced as a result of
extended use policy. The average utilization rate of single-use eye protection and N95 respirators reduced from 1950 to 250
and 2490 to 1710 respectively after implementation. Before extended usage, the N95 respirator utilization per 100 patientdays steadily increased from 400 on 1February to 5428.6 on 8 February (β= 521.22) (Supplementary Appendix Fig. A). After
implementation, theN95 utilization rate dropped to 388.1 on 2 March (β=11.04). Single–use eye protection utilization rate
per 100patient-days was 2076.3 on 1 February and had de-creased to 1411.4 on 3 February (β=−332.45) By 2 March, it
decreased sharply to 32.84 (β= 4.84).

Epidemiology Highlights


Model predicts effect of strategies on the COVID-19 epidemic in the US
J of Macroeconomics: An extended SIR model with agents optimally choosing outdoor activities was created. The model was
calibrated and matched to the data from the United States. The model predicts the epidemic in the United States very well.
Without government intervention, the simulation shows that the epidemic peaks on 22 March, 2020 and ends on 29 August,
2022. By the end of the epidemic, more than 21 million people will be infected, and the death toll is close to 3.8 million. The
model predicts that no single policy can effectively suppress the epidemic, and the most effective policy is a hybrid policy
with lockdown and broadening testing. Lockdown policy alone is ineffective in controlling the epidemic as agents would have
optimally stayed at home anyway if the infection risk is high even without a lockdown. Broadening testing solely will

accelerate the return to normal life as there are fewer infected people hanging around. However, as people do not
internalize the social costs of returning to normal life, the epidemic could get even worse. Increasing medical capacity
without any other measures only has temporary effects on reducing the death toll. Random testing is too inefficient unless a
majority of population is infected.



An index to predict risk of contagion in urban district lockdown
Safety Science: An index was developed to predict the risk of contagion in urban districts to support government
administrations in identifying the best strategies to reduce or restart local activities during lockdown conditions. The index
considers socio-economic data such as the presence of activities, companies, institutions and number of infections in urban
districts. The proposed index is based on a factorial formula, is simple and easy to apply by practitioners, and is calibrated by
using an optimization-based procedure using data from 257 urban districts of the Apulian region (Italy). The index is
compared with a more refined analysis based on the training of Artificial Neural Networks which takes into account the nonlinearity of the phenomenon. The investigation quantifies the influence of each parameter in the risk of contagion.

Practice Guidelines


Institutional antithrombotic protocols for COVID-2019
Research and practice in thrombosis and haemostasis: The authors compare different institutional protocols proposed in US
and France. Here are their summary recommendations: Medical floor COVID-19–positive patients: use LMWH (low molecular
weight heparin) at prophylactic or intermediate doses as the preferred agent over unfractionated heparin (UFH), unless
patients have severe renal insufficiency. Patients with severe COVID-19 requiring high-flow oxygen or ventilator: use LMWH
at prophylactic or intermediate doses as the preferred agent over UFH in ICU settings, with serious illness meeting sepsisinduced coagulopathy score of ≥4 or with markedly elevated D-dimer (>6× ULN). Extended thromboprophylaxis: Patients
hospitalized with COVID-19, especially those with an IMPROVE VTE score of ≥4, elevated D-dimer (>2× ULN), or over 60 years
and without bleeding risk factors, or recent ICU stay should be strongly considered for extended thromboprophylaxis up to
40 days after hospital discharge with either lovenox 40 mg s.c. daily, rivaroxaban 10 mg p.o. daily, or betrixaban 80 mg p.o.
daily. Routine empiric therapeutic dose of intravenous UFH or systemic tissue plasminogen activator or routine use of inferior
vena cava filters: No current supporting evidence for its use without absolute indications. Continuation of home
antithrombotic medications or need of chronic antithrombotic: Patients on antiplatelets or oral anticoagulants (OACs) should
be kept on their therapy unless there are absolute contraindications (such as active bleeding, severe thrombocytopenia,
planned procedure, or significant new drug interaction or other contraindications). DOACs are preferred over warfarin for
treatment of VTE or atrial fibrillation due to decreased need for monitoring. Lopinavir/ritonavir may potentiate CYP3A4 or Pgp inhibition, and as such there may be reduction in clopidogrel effects and increased effects of ticagrelor – thus, switch
them over to prasugrel if possible or consider platelet function studies (P2Y12 monitoring). For OACs, if possible, patients
may be switched to dabigatran, edoxaban, or betrixaban from apixaban and rivaroxaban as the DOACs of choice if combined
therapy with CYP3A4 inhibitor is prescribed. Alternatively, dose-adjusted warfarin with frequent INR monitoring should be a
good option.



The shortcomings of restricted hospital visitation
Pediatric Critical Care Medicine: The authors from the University of Michigan Medical Center warn that severely restricted
visitation policies undermine our ability to provide humane, family-centered care, particularly during critical illness and at the
end of life. The enforcement of these policies consequently increases the risk of moral distress and injury for providers. The
authors surveyed the shortcomings of current visitation restrictions. They argue that hospital visitation restrictions can be
implemented in ways that are nonmaleficent, but this requires unwavering acknowledgment of the value of social and
familial support during illness and death. They advocate that visitation restriction policies be implemented by independent,
medically knowledgeable decision-making bodies, with the informed participation of patients and their families.

Testing


Review of currently available COVID-19 testing
AAS Open Research: Diagnostic tests were developed rapidly for COVID-19, but there is still need for the development of
rapid and specific point-of-care testing. This review outlines different approaches to testing and compares the available test
assays including the Xpert(R) Xpress SARS-CoV-2 test (takes ~45 min) and Abbott ID COVID-19 test (5 min). These assays are
the point-of-care tests for diagnosis of novel COVID-19 that have so far received the US Food and Drug Administration
emergency use authorizations clearance. Improving both the rapidity and sensitivity of testing is key to efforts to contain the
virus.



Effectiveness of various strategies to reduce transmissions in jails and prisons
MedRxiv preprint: COVID-19 presents a serious health risk to the incarcerated population. Depopulation, single occupancy of
cells, and asymptomatic testing can be effective strategies to mitigate transmission in these settings when added to standard
public health measures. Coordination of health care and social services organizations prior to release should be prioritized, as
should testing. The large estimated reduction in the transmission rate (≥ 50%) from these three strategies is comparable to
standard social distancing measures in a community setting.

Drugs, Vaccines, Therapies, Clinical Trials


Further details on the UK RECOVERY dexamethasone trial
Oxford University press release: While the results on the UK RECOVERY trial on the steroid dexamethasone are yet to be
published, it was halted by the Steering Committee because sufficient patients had been enrolled to establish benefit. The
trial web site reported on the effect sizes and their statistical significance. Dexamethasone (6 mg/d for 10 days) reduced
deaths by one-third in ventilated patients (rate ratio 0.65 [95% confidence interval 0.48 to 0.88]; p=0.0003) and by one fifth
in other patients receiving oxygen only (0.80 [0.67 to 0.96]; p=0.0021). There was no benefit among those patients who did
not require respiratory support (1.22 [0.86 to 1.75]; p=0.14).



Methylprednisolone improves outcomes in hospitalized patients with CoVID-19 pneumonia
MedRxiv preprint: A small controlled trial (n = 85) of a short course of methylprednisolone showed improvement of the
composite endpoint of death, ICU admission or requirement of non-invasive ventilation. MP was associated with a reduced
risk of the composite endpoint in the intention-to-treat, age-stratified analysis (combined risk ratio 0.55 [95% CI 0.33-0.91];
p=0.024). A decrease in C-reactive protein levels was more pronounced in the MP group (p=0.0003). Hyperglycemia was
more frequent in the MP group.



Outcomes on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers: a meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy: Review of 16 studies showed conflicting findings on severity and
mortality in patients taking these drugs. In a pooled analysis of four studies, there was a non-significant association of
ACEI/ARB use with lower odds of developing severe disease vs. non-users [OR = 0.81, 95% CI: 0.41-1.58, I2=50.52, P= 0.53). In
a pooled analysis of 6 studies, there was a non-significant association of ACEI/ARB use with lower odds of mortality as
compared with non-users (OR = 0.86, 95% CI = 0.53-1.41, I2 = 79.12, P = 0.55). It is concluded that ACEIs and ARBs should be
continued in COVID-19 patients, reinforcing the recommendations made by several medical societies. Additionally, the
individual patient factors such as ACE2 polymorphisms which might confer higher risk of adverse outcomes need to be
evaluated further.



34 New COVID-19 Trials registered June 17-18 at clinicaltrials.gov
Treatment trials: Hydroxychloroquine, Crizanlizumab, Opaganib, Ivermectin, Tocilizumab, Nitazoxanide, Ciclesonide,
Camostat Mesylate, Microcrystalline Cellulose, Maraviroc, Niclosamide, ketotifen1. At time of writing, a total of 2043 were
active, 161 completed, and 4 posted results.

Other Science


Almost 20% of world’s population has at least one underlying condition raising risk of severe COVID-19
Lancet: UK authors estimated the number of individuals at increased risk of severe disease by age, sex, and country for 188
countries. It was estimated that 1·7 billion people, comprising 22% of the global population, have at least one underlying
condition that puts them at increased risk of severe COVID-19 if infected (ranging from <5% of those younger than 20 years
to >66% of those aged 70 years or older). It was estimated that 349 million (186–787) people (4% [3–9] of the global
population) are at high risk of severe COVID-19 and would require hospital admission if infected (ranging from <1% of those
younger than 20 years to approximately 20% of those aged 70 years or older). It was also estimated that 6% of males are at
high risk compared with 3% of females.



High-flow nasal cannula for acute hypoxemic respiratory failure in COVID-19: systematic reviews
Canadian Journal of Anesthesia: The authors conducted two WHO-commissioned reviews to inform use of high-flow nasal
cannula (HFNC) in patients with COVID-19. They synthesized the evidence regarding efficacy and safety (review 1), as well as
risks of droplet dispersion, aerosol generation, and associated transmission (review 2) of viral products. No eligible studies
included COVID-19 patients. Review 1: 12 RCTs (n = 1,989 patients) provided low-certainty evidence that HFNC may reduce
invasive ventilation (relative risk [RR], 0.85; 95% confidence interval [CI], 0.74 to 0.99) and escalation of oxygen therapy (RR,
0.71; 95% CI, 0.51 to 0.98) in patients with respiratory failure. Results provided no support for differences in mortality
(moderate certainty), or in-hospital or intensive care length of stay (moderate and low certainty, respectively). Review 2: 4
studies evaluating droplet dispersion and three evaluating aerosol generation and dispersion provided very low certainty
evidence. Two simulation studies and a crossover study showed mixed findings regarding the effect of HFNC on droplet
dispersion. Although two simulation studies reported no associated increase in aerosol dispersion, one reported that higher
flow rates were associated with increased regions of aerosol density. Thus, high-flow nasal cannula may reduce the need for
invasive ventilation and escalation of therapy compared with conventional oxygen therapy in COVID-19 patients with acute
hypoxemic respiratory failure. This benefit must be balanced against the unknown risk of airborne transmission.



Genome wide association study of severe Covid-19 with respiratory failure COVID19
NEJM: The authors conducted a genome wide association study involving 1980 patients with Covid-19 and severe disease
(defined as respiratory failure) in Italy and Spain. They analyzed 8,582,968 single-nucleotide polymorphisms and conducted a
meta-analysis of the two case-control panels. They detected cross-replicating associations with rs11385942 at locus 3p21.31
and with rs657152 at locus 9q34.2, which were significant at the genome wide level (P<5×10−8) in the meta-analysis of the
two case–control panels (OR= 1.77; 95% CI, 1.48 to 2.11; p=1.15×10−10; and OR= 1.32; 95% CI, 1.20 to 1.47; p=4.95×10−8,
respectively). At locus 3p21.31, the association signal spanned the genes SLC6A20, LZTFL1, CCR9, FYCO1, CXCR6 and XCR1.
The association signal at locus 9q34.2 coincided with the ABO blood group locus; in this cohort, a blood-group–specific
analysis showed a higher risk in blood group A than in other blood groups (odds ratio, 1.45; 95% CI, 1.20 to 1.75;
P=1.48×10−4) and a protective effect in blood group O as compared with other blood groups (odds ratio, 0.65; 95% CI, 0.53
to 0.79; P=1.06×10−5).



Frailty predicts delirium in elderly hospital and community population with COVID-19
MedRxiv preprint: In this observational study two UK cohorts over 65 yo were explored: hospital cohort (N=322 with
confirmed COVID-19) and community cohort (N=535 reported test-positive for COVID-19). In Hospital cohort, after agematching, delirium was reported in 40 (38%) of frail and 13 (12%) of non-frail patients. Frailty was found to significantly
predict delirium (P=0.013; OR 95% CI = 3.22 (1.44, 7.21)). There were no significant differences between frail and not frail for
other symptoms (fever (temperature ≥ 37.5C) and cough). In community cohort, after age-matching, frailty was found to
significantly predict delirium (P=0.038; OR (95% CI) = 2.29 (1.33, 4.00)), after FDR correction for multiple testing. Frailty also
predicted fatigue (P-value: 0.038; OR = 2.23 (1.27, 3.96)) and shortness of breath (P-value: 0.043; OR = 2.00 (1.19, 3.39)).
There were no significant differences between frail and not frail for the other 11 symptoms analyzed. Systematic frailty
assessment and screening for delirium in acutely ill older patients in hospital and community settings is needed. Clinicians
should suspect COVID-19 in frail adults with delirium.



Asymptomatic individuals with SARS-CoV-2 have a longer shedding and weaker immune response
Nature Medicine: The authors studied 37 asymptomatic individuals in China with SARS-CoV-2 in the preceding 14 days and

during hospitalization. The median duration of viral shedding in the asymptomatic group was 19 days (interquartile range
(IQR), 15–26 d). The asymptomatic group had a significantly longer duration of viral shedding than the symptomatic group
(log-rank P= 0.028). The virus-specific IgG levels in the asymptomatic group (median S/CO, 3.4; IQR, 1.6–10.7) were
significantly lower (P= 0.005) relative to the symptomatic group (median S/CO, 20.5; IQR, 5.8–38.2) in the acute phase. Of
asymptomatic individuals, 93.3% (28/30) and 81.1% (30/37) had reduction in IgG and neutralizing antibody levels,
respectively, during the early convalescent phase, as compared to 96.8% (30/31) and 62.2% (23/37) of symptomatic patients.
40% of asymptomatic individuals became seronegative and 12.9% of the symptomatic group became negative for IgG in the
early convalescent phase. Asymptomatic individuals had lower levels of 18 pro- and anti-inflammatory cytokines.

Contributing team members: Christophe G. Lambert, Shawn Stoicu, Ingrid Hendrix, Lori Sloane, Mari Anixter,
Anastasiya Nestsiarovich, Praveen Kumar, Nicolas Lauve, Morgan Edwards-Fligner, Emma Wolinsky, Alexandra
Yingling, Kristine Tollestrup, Orrin Myers, Douglas J. Perkins.
Disclaimer: The UNM Global Health COVID-19 Briefing is provided as a public service. Sources include not only
peer-reviewed literature, but also preliminary research manuscripts that have not been peer reviewed along
with lay news media reports. The peer-review process often results in manuscript improvement, with
corrections made for errors and unsubstantiated conclusions being corrected. Furthermore, many headlines
and summaries in the briefing are written by student volunteers and others who may lack subject matter
expertise in this rapidly evolving field. As such, the headlines and summaries should not be regarded as
conclusive. Instead, readers are encouraged to use the briefing to identify areas of interest and then use the
embedded links to read and critically evaluate the primary sources.

